No Photo Available

Last Update

2014-02-28T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Matti Aapro?

Matti S. Aapro

Medical Oncologist

Institute of Cancer Policy

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Institute of Cancer Policy

Background Information

Employment History

AlphaMed Press

Web References (6 Total References)


"Biosimilars ultimately mean more ...

www.instituteofcancerpolicy.org [cached]

"Biosimilars ultimately mean more competition, and more competition should result in prices for oncology drugs going down," said Matti Aapro, a medical oncologist from the Clinique de Genolier, Switzerland.

...
Longer and larger studies are needed," explained Aapro.
Lagging behind is the FDA, who is still in the process of debating draft guidelines produced in 2012, and considering issues such as how close copies should be to the originator drug and how biosimilars should be named and labelled.
One thorny subject is whether the FDA can approve biosimilars based on reference products that have been approved overseas, but not in the US.
"For the US the fact that a biosimilar regulatory pathway has not been established is limiting competition and causing delays in reducing the cost of drugs," said Aapro.
Nations in Asia Pacific, Latin America and Eastern Europe are also in the process of establishing biosimilar regulatory pathways, providing sponsors with opportunities to select research sites strategically to optimise development timelines and achieve registration goals.
Oncologists using biosimilars or generic products need to be aware that switching patients from one agent to a similar but 'not quite identical product' could have important clinical consequences.
"Many of these drugs have narrow windows of efficacy versus toxicity, and switching from drug A to drug B could have a major effect," cautioned Aapro.
It is vital, he added, that drugs dispensed to patients should be clearly labelled and not automatically substituted, so that the drugs responsible for any adverse effects can be traced.


Matti S. Aapro The ...

Theoncologistcommunity.com [cached]

Matti S. Aapro The Oncologist 2008; 13(Supplement 3): 1-3; doi:10.1634/theoncologist.13-S3-1

...
Matti S. Aapro, Hartmut Link The Oncologist 2008; 13(Supplement 3): 33-36; doi:10.1634/theoncologist.13-S3-33


Matti S. ...

www.theoncologistcommunity.com [cached]

Matti S. Aapro The Oncologist 2008; 13(Supplement 3): 1-3; doi:10.1634/theoncologist.13-S3-1

...
Matti S. Aapro, Hartmut Link The Oncologist 2008; 13(Supplement 3): 33-36; doi:10.1634/theoncologist.13-S3-33


Matti S. Aapro ...

theoncologist.alphamedpress.org [cached]

Matti S. Aapro The Oncologist 2008; 13(Supplement 3): 1-3; doi:10.1634/theoncologist.13-S3-1

...
Matti S. Aapro, Hartmut Link The Oncologist 2008; 13(Supplement 3): 33-36; doi:10.1634/theoncologist.13-S3-33


The Oncologist Online -- Table of Contents Volume 11, Supplement 1, 2006

theoncologist.alphamedpress.org [cached]

David Cameron, Richard Bell, Matti Aapro, Christoph Zielinski

Similar Profiles

Other People with this Name

Other people with the name Aapro

Matti Aapro
European School of Oncology

Matti Aapro
Elsevier B.V

Matti Aapro
Kenes International

Kari Aapro
NATO

Christopher Aapro
Eliittikatot Oy

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory